Clinical and immunophenotypic features of age-related EBV LPD tumors
No. . | Age, y . | Sex . | Biopsy specimen . | CD15 . | CD20 . | CD30 . | CD45 . | CD79a . | EBER . | LMP1 . | EBNA2 . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 79 | M | Skin | 0 | 2+ | 2+ | 1+ | 2+ | 2+ | 1+ | 2+ |
2 | 82 | M | Cervical LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | 2+ | 2+ |
3 | 88 | M | Cervical LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
4 | 79 | F | Skin | 0 | 2+ | 1+ | 1+ | 2+ | 2+ | 2+ | 0 |
5 | 63 | F | Lung, stomach | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 2+ |
6 | 73 | F | Skin, LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | 2+ | 0 |
7 | 83 | M | Pharynx | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
8 | 68 | M | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
9 | 85 | M | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
10 | 78 | M | Spleen | 0 | 2+ | 0 | 1+ | 2+ | 2+ | 2+ | 2+ |
11 | 78 | F | LN | 0 | NS | 0 | 2+ | 2+ | 2+ | 2+ | 2+ |
12 | 71 | F | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
13 | 70 | F | Stomach | 2+ | 2+ | 2+ | 0 | ||||
14 | 64 | F | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
15 | 67 | F | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
16 | 63 | F | Tonsil | 0 | 2+ | 1+ | 2+ | 2+ | 2+ | 0 | |
17 | 50 | M | Stomach | 0 | 2+ | 2+ | 2+ | ||||
18 | 68 | M | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
19 | 65 | F | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
20 | 81 | F | LN | 0 | 2+ | 1+ | 0 | 2+ | 2+ | ||
21 | 71 | F | LN | 0 | 2+ | 1+ | 2+ | 1+ | 0 | ||
22 | 86 | M | Nasal cavity | 0 | 2+ | 0 | 2+ | 2+ | 1+ | 2+ | |
23 | 78 | M | LN | 2+ | 2+ | 2+ | 2+ | 0 | |||
24 | 63 | M | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
25 | 54 | M | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
26 | 55 | F | Tonsil | 0 | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | |
27 | 73 | M | LN | 2+ | 2+ | ||||||
28 | 61 | F | Skin | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
29 | 55 | M | LN | 2+ | 2+ | ||||||
30 | 71 | M | LN | 2+ | 2+ | 2+ | 2+ | NS | |||
31 | 79 | M | LN | 2+ | 2+ | ||||||
32 | 74 | M | Media-LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | NS | |
33 | 66 | M | LN | 2+ | 2+ | 2+ | 2+ | ||||
34 | 82 | M | LN | 0 | NS | 2+ | 2+ | 2+ | 2+ | 0 |
No. . | Age, y . | Sex . | Biopsy specimen . | CD15 . | CD20 . | CD30 . | CD45 . | CD79a . | EBER . | LMP1 . | EBNA2 . |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 79 | M | Skin | 0 | 2+ | 2+ | 1+ | 2+ | 2+ | 1+ | 2+ |
2 | 82 | M | Cervical LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | 2+ | 2+ |
3 | 88 | M | Cervical LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
4 | 79 | F | Skin | 0 | 2+ | 1+ | 1+ | 2+ | 2+ | 2+ | 0 |
5 | 63 | F | Lung, stomach | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 2+ |
6 | 73 | F | Skin, LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | 2+ | 0 |
7 | 83 | M | Pharynx | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
8 | 68 | M | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
9 | 85 | M | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
10 | 78 | M | Spleen | 0 | 2+ | 0 | 1+ | 2+ | 2+ | 2+ | 2+ |
11 | 78 | F | LN | 0 | NS | 0 | 2+ | 2+ | 2+ | 2+ | 2+ |
12 | 71 | F | LN | 0 | 2+ | 0 | 0 | 2+ | 2+ | 2+ | 0 |
13 | 70 | F | Stomach | 2+ | 2+ | 2+ | 0 | ||||
14 | 64 | F | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
15 | 67 | F | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
16 | 63 | F | Tonsil | 0 | 2+ | 1+ | 2+ | 2+ | 2+ | 0 | |
17 | 50 | M | Stomach | 0 | 2+ | 2+ | 2+ | ||||
18 | 68 | M | LN | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
19 | 65 | F | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
20 | 81 | F | LN | 0 | 2+ | 1+ | 0 | 2+ | 2+ | ||
21 | 71 | F | LN | 0 | 2+ | 1+ | 2+ | 1+ | 0 | ||
22 | 86 | M | Nasal cavity | 0 | 2+ | 0 | 2+ | 2+ | 1+ | 2+ | |
23 | 78 | M | LN | 2+ | 2+ | 2+ | 2+ | 0 | |||
24 | 63 | M | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
25 | 54 | M | LN | 0 | 2+ | 2+ | 2+ | 2+ | 0 | ||
26 | 55 | F | Tonsil | 0 | 2+ | 2+ | 2+ | 2+ | 2+ | 2+ | |
27 | 73 | M | LN | 2+ | 2+ | ||||||
28 | 61 | F | Skin | 0 | 2+ | 1+ | 2+ | 2+ | 0 | ||
29 | 55 | M | LN | 2+ | 2+ | ||||||
30 | 71 | M | LN | 2+ | 2+ | 2+ | 2+ | NS | |||
31 | 79 | M | LN | 2+ | 2+ | ||||||
32 | 74 | M | Media-LN | 0 | 2+ | 2+ | 0 | 2+ | 2+ | NS | |
33 | 66 | M | LN | 2+ | 2+ | 2+ | 2+ | ||||
34 | 82 | M | LN | 0 | NS | 2+ | 2+ | 2+ | 2+ | 0 |
Scoring for the expression of immunophenotypic markers: 0 indicates a negative stain; 1+, positive on less than 50% of tumor cells; and 2+, positive on more than 50%.
LPD indicates lymphoproliferative disorder; LN, lymph node; and NS, not satisfactory.